Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Aave Wallet Growth Hits 5-Year High Even as Standard Chartered Revises Crypto Forecasts

Aave Wallet Growth Hits 5-Year High Even as Standard Chartered Revises Crypto Forecasts

BeInCryptoBeInCrypto2026/07/02 02:00
By:BeInCrypto
Aave logged its largest single-day wallet growth in nearly five years, with 1,806 new addresses created on Ethereum on June 30, according to on-chain analytics firm Santiment. The surge lines up with a $3,500 price target on Aave (AAVE) from Standard Chartered, a bank that has repeatedly cut its own Bitcoin (BTC) and Ethereum (ETH) forecasts this year. A Familiar Pattern of Forecasts Standard Chartered initiated coverage of AAVE with a target implying nearly 50 times upside by 2030, built on an Aave $3,500 forecast tied to tokenized assets flooding decentralized finance (DeFi). The bank made a similar call on Uniswap (UNI) weeks earlier, and that forecast also triggered a jump in Uniswap network activity before it cooled off. ✍️ TL;DR: AAVE (On Ethereum) ends June with its highest network growth day since 2021📊 Metrics used: Network Growth📈 Aave (on Ethereum) has just seen 1,806 new wallets created in 24 hours, marking its strongest network growth day Santiment Intelligence (@SantimentData) July 1, 2026 The same research desk cut its 2026 Bitcoin target from $150,000 to $100,000 and slashed its Ethereum price target 47%, from $7,500 to $4,000, within the same three-month stretch. We forecast significant upside for digital asset token prices into year-end, and we think Aave has moved beyond the April incident.Geoff Kendrick, Standard Chartered That April incident was the KelpDAO exploit, which drained roughly $292 million and fed a KelpDAO exploit fallout that briefly cut Aaves deposits nearly in half. Aave has since restarted its AAVE buyback program under Aavenomics 3.0, confirmed by founder Stani Kulechov, adding a direct revenue-to-token mechanism behind the current move. Whether new wallets convert into deposits and borrowing, rather than short-lived attention, will decide if Aaves growth outlasts Standard Chartereds own forecasting record. Read the article at BeInCrypto
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "Outlier" Investment Art in the New Era of Berky

他山之石观投资2026/09/14 09:22
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

智通财经2026/09/14 09:12
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

智通财经2026/09/14 08:57
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales

Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

智通财经2026/09/14 08:41
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales